{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:35:56Z","timestamp":1785332156778,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00393-009-0542-3","type":"journal-article","created":{"date-parts":[[2009,9,14]],"date-time":"2009-09-14T09:43:12Z","timestamp":1252921392000},"page":"766-771","source":"Crossref","is-referenced-by-count":6,"title":["Empfehlungen zur Therapie mit Interleukin-1\u03b2-blockierenden Wirkstoffen","Recommendations on therapy using interleukin-1\u03b2-blocking agents"],"prefix":"10.1007","volume":"68","author":[{"name":"Kommission Pharmakotherapie der DGRh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Manger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gaubitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,9]]},"reference":[{"key":"542_CR1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00393-002-0452-0","volume":"61","author":"Manger","year":"2002","unstructured":"Manger B (2002) Empfehlungen der Deutschen Gesellschaft f\u00fcr Rheumatologie zur Therapie der rheumatoiden Arthritis mit dem IL-1-Rezeptorantagonisten Anakinra (Kineret\u00ae). Z Rheumatol 61(6):698\u2013700","journal-title":"Z Rheumatol"},{"key":"542_CR2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2001.23701","volume":"30","author":"Bresnihan","year":"2001","unstructured":"Bresnihan B (2001) The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 30(5 Suppl 2):17\u201320","journal-title":"Semin Arthritis Rheum"},{"key":"542_CR3","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","volume":"41","author":"Bresnihan","year":"1998","unstructured":"Bresnihan B, Alvaro-Gracia JM, Cobby M et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41(12):2196\u20132204","journal-title":"Arthritis Rheum"},{"key":"542_CR4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","volume":"46","author":"Cohen","year":"2002","unstructured":"Cohen S, Hurd E, Cush J et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3):614\u2013624","journal-title":"Arthritis Rheum"},{"key":"542_CR5","first-page":"1103","volume":"31","author":"Bresnihan","year":"2004","unstructured":"Bresnihan B, Newmark R, Robbins S, Genant HK (2004) Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 31(6):1103\u20131111","journal-title":"J Rheumatol"},{"key":"542_CR6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","volume":"43","author":"Jiang","year":"2000","unstructured":"Jiang Y, Genant HK, Watt I et al (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43(5):1001\u20131009","journal-title":"Arthritis Rheum"},{"key":"542_CR7","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2008.100834","volume":"67","author":"Furst","year":"2008","unstructured":"Furst DE, Keystone EC, Kirkham B et al (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67 (Suppl 3):iii2\u2013iii25","journal-title":"Ann Rheum Dis"},{"key":"542_CR8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","volume":"36","author":"Mertens","year":"2009","unstructured":"Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: A systematic review. J Rheumatol 36(6):1118\u20131125","journal-title":"J Rheumatol"},{"key":"542_CR9","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","volume":"52","author":"Fitzgerald","year":"2005","unstructured":"Fitzgerald AA, Leclercq SA, Yan A et al (2005) Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease. Arthritis Rheum 52(6):1794\u20131803","journal-title":"Arthritis Rheum"},{"key":"542_CR10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/ard.2004.026617","volume":"64","author":"Vasques","year":"2005","unstructured":"Vasques Godinho FM, Parreira Santos MJ, Canas da SJ (2005) Refractory adult onset Still\u2019s disease successfully treated with anakinra. Ann Rheum Dis 64(4):647\u2013648","journal-title":"Ann Rheum Dis"},{"key":"542_CR11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"Lequerre","year":"2008","unstructured":"Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67(3):302\u2013308","journal-title":"Ann Rheum Dis"},{"key":"542_CR12","first-page":"415","volume":"67","author":"Manger","year":"2008","unstructured":"Manger B (2008) Der adulte Morbus Still. Z Rheumatol 67(5):415\u2013422","journal-title":"Z Rheumatol"},{"key":"542_CR13","first-page":"758","volume":"25","author":"Guignard","year":"2007","unstructured":"Guignard S, Dien G, Dougados M (2007) Severe systemic inflammatory response syndrome in a patient with adult onset Still\u2019s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 25(5):758\u2013759","journal-title":"Clin Exp Rheumatol"},{"key":"542_CR14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/ard.2006.060541","volume":"66","author":"Ruiz","year":"2007","unstructured":"Ruiz PJ, Masliah E, Doherty TA et al (2007) Cardiac death in a patient with adult-onset Still\u2019s disease treated with the interleukin 1 receptor inhibitor anakinra. Ann Rheum Dis 66(3):422\u2013423","journal-title":"Ann Rheum Dis"},{"key":"542_CR15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/ard.2005.042143","volume":"65","author":"Efthimiou","year":"2006","unstructured":"Efthimiou P, Paik PK, Bielory L (2006) Diagnosis and management of adult onset Still\u2019s disease. Ann Rheum Dis 65(5):564\u2013572","journal-title":"Ann Rheum Dis"},{"key":"542_CR16","doi-asserted-by":"crossref","first-page":"P27","DOI":"10.1186\/1546-0096-6-S1-P27","volume":"6","author":"Quartier","year":"2008","unstructured":"Quartier P, Allantaz F, Cimaz R et al (2008) Efficacy, safety and effect on gene expression profiling of anakinra in systemic-onset juvenile idiopathic arthritis: final results of a randomised, placebo-controlled trial (ANAJIS). Pediatr Rheumatol 6 (Suppl I):P27","journal-title":"Pediatr Rheumatol"},{"key":"542_CR17","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasiglie D et al (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58(5):1505\u20131515","journal-title":"Arthritis Rheum"},{"key":"542_CR18","doi-asserted-by":"crossref","unstructured":"Ohlsson V, Baildam E, Foster H et al (2008) Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47(4):555\u2013556","DOI":"10.1093\/rheumatology\/ken030"},{"key":"542_CR19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479\u20131486","journal-title":"J Exp Med"},{"key":"542_CR20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0028-1086037","volume":"220","author":"Guellac","year":"2008","unstructured":"Guellac N, Niehues T (2008) Interdisziplin\u00e4re S2-Leitlinie der juvenilen idiopathischen Arthritis. Klin P\u00e4diatr 220(6):392\u2013402","journal-title":"Klin P\u00e4diatr"},{"key":"542_CR21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0037-1620152","volume":"29","author":"Horneff","year":"2009","unstructured":"Horneff G (2009) Die medikament\u00f6se Therapie der juvenilen idiopathischen Arthritis bei Kindern. Arthritis Rheum 29(2):81\u201393","journal-title":"Arthritis Rheum"},{"key":"542_CR22","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","volume":"360","author":"Aksentijevich","year":"2009","unstructured":"Aksentijevich I, Masters SL, Ferguson PJ et al (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360(23):2426\u20132437","journal-title":"N Engl J Med"},{"key":"542_CR23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/03009748709102523","volume":"66","author":"Prieur","year":"1987","unstructured":"Prieur AM, Griscelli C, Lampert F et al (1987) A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 66:57\u201368","journal-title":"Scand J Rheumatol Suppl"},{"key":"542_CR24","first-page":"127","volume":"305","author":"Brydges","year":"2006","unstructured":"Brydges S, Kastner DL (2006) The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol 305:127\u2013160","journal-title":"Curr Top Microbiol Immunol"},{"key":"542_CR25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/bor.0000174210.78449.6b","volume":"17","author":"Stojanov","year":"2005","unstructured":"Stojanov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17(5):586\u2013599","journal-title":"Curr Opin Rheumatol"},{"key":"542_CR26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0049-0172(98)80028-0","volume":"28","author":"Ben-Chetrit","year":"1998","unstructured":"Ben-Chetrit E, Levy M (1998) Colchicine: 1998 update. Semin Arthritis Rheum 28(1):48\u201359","journal-title":"Semin Arthritis Rheum"},{"key":"542_CR27","first-page":"1302","volume":"287","author":"Goldfinger","year":"1972","unstructured":"Goldfinger SE (1972) Colchicine for familial Mediterranean fever. N Engl J Med 287(25):1302","journal-title":"N Engl J Med"},{"key":"542_CR28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/art.20033","volume":"50","author":"Hawkins","year":"2004","unstructured":"Hawkins PN, Lachmann HJ, Aganna E, McDermott MF (2004) Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 50(2):607\u2013612","journal-title":"Arthritis Rheum"},{"key":"542_CR29","doi-asserted-by":"crossref","unstructured":"Dybowski F, Jakobs B, Altmeyer P, Braun J (2006) Erfolgreiche Behandlung der klinischen Manifestationen des Muckle-Wells-Syndroms mit Anakinra. Dtsch Med Wochenschr 131(34\u201335):1863\u20131866","DOI":"10.1055\/s-2006-949170"},{"key":"542_CR30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","volume":"355","author":"Goldbach-Mansky","year":"2006","unstructured":"Goldbach-Mansky R, Dailey NJ, Canna SW et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6):581\u2013592","journal-title":"N Engl J Med"},{"key":"542_CR31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.20953","volume":"52","author":"Lovell","year":"2005","unstructured":"Lovell DJ, Bowyer SL, Solinger AM (2005) Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 52(4):1283\u20131286","journal-title":"Arthritis Rheum"},{"key":"542_CR32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/art.21807","volume":"54","author":"Mirault","year":"2006","unstructured":"Mirault T, Launay D, Cuisset L et al (2006) Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 54(5):1697\u20131700","journal-title":"Arthritis Rheum"},{"key":"542_CR33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1525-1470.2007.00343.x","volume":"24","author":"O","year":"2007","unstructured":"O\u2019Connell SM, O\u2019Regan GM, Bolger T et al (2007) Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 24(1):85\u201389","journal-title":"Pediatr Dermatol"},{"key":"542_CR34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/ard.2005.038091","volume":"65","author":"Rynne","year":"2006","unstructured":"Rynne M, Maclean C, Bybee A et al (2006) Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis 65(4):533\u2013534","journal-title":"Ann Rheum Dis"},{"key":"542_CR35","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.23261","volume":"58","author":"Yamazaki","year":"2008","unstructured":"Yamazaki T, Masumoto J, Agematsu K et al (2008) Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum 58(3):864\u2013868","journal-title":"Arthritis Rheum"},{"key":"542_CR36","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/archderm.142.12.1591","volume":"142","author":"Leslie","year":"2006","unstructured":"Leslie KS, Lachmann HJ, Bruning E et al (2006) Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1\/NALP3 mutations. Arch Dermatol 142(12):1591\u20131597","journal-title":"Arch Dermatol"},{"key":"542_CR37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-146-11-200706050-00023","volume":"146","author":"Belkhir","year":"2007","unstructured":"Belkhir R, Moulonguet-Doleris L, Hachulla E et al (2007) Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 146(11):825\u2013826","journal-title":"Ann Intern Med"},{"key":"542_CR38","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10545-006-0408-7","volume":"29","author":"Cailliez","year":"2006","unstructured":"Cailliez M, Garaix F, Rousset-Rouviere C et al (2006) Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 29(6):763","journal-title":"J Inherit Metab Dis"},{"key":"542_CR39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00431-007-0547-3","volume":"167","author":"Calligaris","year":"2008","unstructured":"Calligaris L, Marchetti F, Tommasini A, Ventura A (2008) The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 167(6):695\u2013696","journal-title":"Eur J Pediatr"},{"key":"542_CR40","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/art.23475","volume":"58","author":"Gattorno","year":"2008","unstructured":"Gattorno M, Pelagatti MA, Meini A et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58(5):1516\u20131520","journal-title":"Arthritis Rheum"},{"key":"542_CR41","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1365-2362.2007.01868.x","volume":"37","author":"Gattringer","year":"2007","unstructured":"Gattringer R, Lagler H, Gattringer KB et al (2007) Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 37(11):912\u2013914","journal-title":"Eur J Clin Invest"},{"key":"542_CR42","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/ard.2007.071498","volume":"66","author":"Kuijk","year":"2007","unstructured":"Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ (2007) Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66(11):1545\u20131546","journal-title":"Ann Rheum Dis"},{"key":"542_CR43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00296-006-0164-x","volume":"27","author":"Rigante","year":"2006","unstructured":"Rigante D, Ansuini V, Bertoni B et al (2006) Treatment with anakinra in the hyperimmunoglobulinemia D\/periodic fever syndrome. Rheumatol Int 27(1):97\u2013100","journal-title":"Rheumatol Int"},{"key":"542_CR44","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jbspin.2007.01.032","volume":"74","author":"Gerard","year":"2007","unstructured":"Gerard S, le GB, Maugars Y et al (2007) Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra. Joint Bone Spine 74(6):659","journal-title":"Joint Bone Spine"},{"key":"542_CR45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64(2):296\u2013298","journal-title":"Ann Rheum Dis"},{"key":"542_CR46","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/ard.2004.020800","volume":"63","author":"Tan","year":"2004","unstructured":"Tan AL, Marzo-Ortega H, O\u2019Connor P et al (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63(9):1041\u20131045","journal-title":"Ann Rheum Dis"},{"key":"542_CR47","first-page":"S719","volume":"54","author":"Gibbs","year":"2006","unstructured":"Gibbs A, Gogarty M, Bresnihan B et al (2006) Moderate clinical response and absence of MRI or immunohistological change suggest that Anakinra is ineffective in psoriatic arthritis. Arthritis Rheum 54 (Suppl):S719","journal-title":"Arthritis Rheum"},{"key":"542_CR48","first-page":"1092","volume":"64","author":"Jung","year":"2005","unstructured":"Jung N, Hoheisel R, Haase I et al (2005) Anakinra (IL-1RA) in the treatment of patients with active psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Ann Rheum Dis 64 (Suppl III):1092","journal-title":"Ann Rheum Dis"},{"key":"542_CR49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","volume":"28","author":"Ilowite","year":"2009","unstructured":"Ilowite N, Porras O, Reiff A et al (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28(2):129\u2013137","journal-title":"Clin Rheumatol"},{"key":"542_CR50","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/art.23620","volume":"58","author":"Goldbach-Mansky","year":"2008","unstructured":"Goldbach-Mansky R, Shroff SD, Wilson M et al (2008) A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 58(8):2432\u20132442","journal-title":"Arthritis Rheum"},{"key":"542_CR51","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"Hoffman","year":"2008","unstructured":"Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58(8):2443\u20132452","journal-title":"Arthritis Rheum"},{"key":"542_CR52","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar2438","volume":"10","author":"Alten","year":"2008","unstructured":"Alten R, Gram H, Joosten LA et al (2008) The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10(3):R67","journal-title":"Arthritis Res Ther"},{"key":"542_CR53","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1185\/03007990802297495","volume":"24","author":"Hoffman","year":"2008","unstructured":"Hoffman HM, Wolfe F, Belomestnov P, Mellis SJ (2008) Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin 24(9):2531\u20132543","journal-title":"Curr Med Res Opin"},{"key":"542_CR54","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360(23):2416\u20132425","journal-title":"N Engl J Med"},{"key":"542_CR55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1546-0096-6-S1-S1","volume":"6","author":"Ruperto","year":"2008","unstructured":"Ruperto N, Quartier P, Wulffraat N et al (2008) A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA). Pediatr Rheumatol 6 (Suppl 1):S1\u2013S2","journal-title":"Pediatr Rheumatol"},{"key":"542_CR56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/art.23119","volume":"58","author":"McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Madden J et al (2008) Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58(2):631\u2013633","journal-title":"Arthritis Rheum"},{"key":"542_CR57","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"So","year":"2007","unstructured":"So A, De ST, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28","journal-title":"Arthritis Res Ther"},{"key":"542_CR58","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","volume":"66","author":"McGonagle","year":"2007","unstructured":"McGonagle D, Tan AL, Shankaranarayana S et al (2007) Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66(12):1683\u20131684","journal-title":"Ann Rheum Dis"},{"key":"542_CR59","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","volume":"149","author":"Botsios","year":"2008","unstructured":"Botsios C, Sfriso P, Furlan A et al (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149(4):284\u2013286","journal-title":"Ann Intern Med"},{"key":"542_CR60","doi-asserted-by":"crossref","unstructured":"Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C (2006) Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 45(4):491\u2013492","DOI":"10.1093\/rheumatology\/kel041"},{"key":"542_CR61","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jbspin.2008.02.011","volume":"75","author":"Wendling","year":"2008","unstructured":"Wendling D, Govindaraju S, Prati C et al (2008) Efficacy of anakinra in a patient with refractory relapsing polychondritis. Joint Bone Spine 75(5):622\u2013624","journal-title":"Joint Bone Spine"},{"key":"542_CR62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2007.04.001","volume":"37","author":"de","year":"2007","unstructured":"de Koning HD, Bodar EJ, van der Meer JW, Simon A (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37(3):137\u2013148","journal-title":"Semin Arthritis Rheum"},{"key":"542_CR63","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.jaad.2006.05.057","volume":"56","author":"Schneider","year":"2007","unstructured":"Schneider SW, Gaubitz M, Luger TA, Bonsmann G (2007) Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol 56(5 Suppl):S120\u2013S122","journal-title":"J Am Acad Dermatol"},{"key":"542_CR64","doi-asserted-by":"crossref","unstructured":"Thonhofer R, Uitz E, Graninger W (2007) Schnitzler\u2019s syndrome\u2013exacerbation after anti-TNF treatment. Rheumatology (Oxford) 46(6):1041\u20131042","DOI":"10.1093\/rheumatology\/kem048"},{"key":"542_CR65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaad.2007.03.036","volume":"57","author":"Eiling","year":"2007","unstructured":"Eiling E, Moller M, Kreiselmaier I et al (2007) Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J Am Acad Dermatol 57(2):361\u2013364","journal-title":"J Am Acad Dermatol"},{"key":"542_CR66","first-page":"354","volume":"26","author":"Dybowski","year":"2008","unstructured":"Dybowski F, Sepp N, Bergerhausen HJ, Braun J (2008) Successful use of anakinra to treat refractory Schnitzler\u2019s syndrome. Clin Exp Rheumatol 26(2):354\u2013357","journal-title":"Clin Exp Rheumatol"},{"key":"542_CR67","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1191\/0961203304lu1047cr","volume":"13","author":"Moosig","year":"2004","unstructured":"Moosig F, Zeuner R, Renk C, Schroder JO (2004) IL-1RA in refractory systemic lupus erythematosus. Lupus 13(8):605\u2013606","journal-title":"Lupus"},{"key":"542_CR68","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.2004.025858","volume":"64","author":"Ostendorf","year":"2005","unstructured":"Ostendorf B, Iking-Konert C, Kurz K et al (2005) Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 64(4):630\u2013633","journal-title":"Ann Rheum Dis"},{"key":"542_CR69","first-page":"2081","volume":"33","author":"Behrens","year":"2006","unstructured":"Behrens EM, Kreiger PA, Cherian S, Cron RQ (2006) Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol 33(10):2081\u20132084","journal-title":"J Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0542-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0542-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0542-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:36:00Z","timestamp":1559046960000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0542-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,9]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0542-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,9]]}}}